Purpose of Review The purpose of this study is to describe the pathology, impact of comorbidities, functional limitations, symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in older adults. Recent Findings AML is a rare aggressive hematologic disease that occurs most often in older adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and patient characteristics such as comorbidities and functional limitations. Patient characteristics may influence treatment decisions, as well as impact symptoms, functional ability, health-related outcomes, and QOL. Summary As the population continues to age, the number of people diagnosed with AML is expected to increase. Better management of comorbidities is imperative to improving QOL and other treatment-related outcomes. Prospective, longitudinal, and multi-site studies are warranted to further understand the interaction between these characteristics on symptoms, outcomes, and QOL.
Introduction
Acute myeloid leukemia (AML) is a rare aggressive hematologic disease that afflicts 3-4 persons per 100,000 individuals annually [1••, 2]. In the United States, estimates predict 21,830 new cases of AML with approximately 10,590 AML-related deaths in 2017 [3] . The risk for AML increases with age, and recent Surveillance Epidemiology and End Results Data (SEER) indicates that over 70% of new AML cases are diagnosed in adults ≥55 years of age with the median age of diagnosis being 67 years of age [1, 4] . The prognosis for older patients diagnosed with AML is notably worse due to poor cytogenetic characteristics, genetic mutations that confer resistance to chemotherapy, and patient clinical characteristics such as comorbidities and physical function [5, 6••] .
AML is a disease of the hematopoietic system in the bone marrow resulting in a transformation of leukocytes and leukocyte precursors into malignant cells [7] . A large number of these immature, abnormal cells proliferate rapidly and accumulate in the bone marrow suppressing the hematopoietic system [7] . The etiology of leukemia is unknown, environmental exposure, genetic characteristics and the process of aging can cause a gradual deterioration of the immune system (immunosenescence), increasing the risk for the development of AML [8] . The normal aging process creates a milieu of persistent low-grade inflammation, known as "inflammaging" which is characterized by increased levels of circulating proinflammatory cytokines (IL-1, IL-6 and TNF-α) [9, 10] . These pro-inflammatory cytokines facilitate cellular aberrations that decrease the ability of the immune system to conduct Continuous exposure of cells to systemic inflammation throughout the aging process is a contributing factor in the increased vulnerability to cancer, infectious diseases, diabetes, heart disease, neurodegeneration, and other age-related chronic comorbid diseases [9, 10, 13]. Additionally, environmental exposures to benzene and ionizing radiation have also been associated with an increased risk for leukemias [14] . The treatment regimen for AML is aggressive and associated with high acuity, fluctuating symptoms, and high financial cost. Standard regimens involve cycles of induction chemotherapy, consolidation chemotherapy, and when appropriate, allogeneic hematopoietic cell transplantation, with the goal of achieving complete remission with possible cure of the disease [15, 16] . Older individuals, often do not tolerate aggressive therapies and are more likely to experience poor health outcomes such as longer neutropenia (low white blood cell count), increased rates of infection, and longer hospital length of stay [17, 18, 19••] . Additionally, older patients with AML are less likely to achieve complete remission and remain relapse free compared to their younger counterparts [15, 20] . The disparity in these outcomes among younger versus older patients (< 60 years of age versus ≥ 60 years of age) may be due to differences in cytogenetics, subsequent resistance to chemotherapy, treatment-related toxicity, immune suppression resulting in increased vulnerability to bacterial and fungal infections, decreased physical functional reserve, organ dysfunction, and/or comorbidities Changes to physical and functional abilities may be exacerbated due to the treatment regimens for AML. Side effects from treatment, in addition to managing comorbidities, can affect health outcomes and overall quality of life (QOL). Managing comorbidities, improving health outcomes, and maintaining QOL for older patients with AML is important to consider during and after treatment. Little is known regarding the impact of comorbidities, physical function, and symptoms on the QOL and health outcomes of older patients receiving treatment for AML. Therefore, the purpose of this short review is to describe comorbidity, symptoms, and QOL experienced by older adults with AML. Specifically, this review will focus on the comorbidities and measures used in AML, and QOL related to treatment in older adults with AML.
Comorbidities and AML
Advanced age is often accompanied by frailty and comorbidities, which have an important impact on the tolerance that older patients diagnosed with AML may have to intensive treatment modalities [1••] . Treatment choice also depends on a variety of factors, including age, performance status, and comorbidities [24] . Studies have shown older patients with AML can benefit from standard therapy regimens; however, there is often reluctance among clinicians especially in the presence of comorbidities due to the difficulty of predicting risk/benefits of available therapies [11••, 17, 25] . Concern of treatment toxicity and/or mortality may influence clinicians' decisions regarding treatment regimen and/or reduction in the intensity of treatment [11••] .
Researchers have demonstrated that comorbidities are an independent predictor of all-cause mortality in patients with AML [21, 23••, 26••]. In one prospective observational study examining change in QOL scores and their association with therapy and survival in older adults with AML, researchers found at least one comorbid disease was present in 70% patients with AML in the palliative treatment group and 48% of those in the intensive treatment group [15] . Several important prognostic factors for AML such as age, gender, and socioeconomic status are associated with comorbidity, and these factors may potentially explain the adverse effect of comorbidity on prognosis [27] .
There are also health-related outcomes to consider when examining treatment related to older adults with AML. For example, studies of older adults with AML have shown a relationship between increased comorbidity burden and worse outcomes including toxicity, hospital readmission rates, 30-day mortality, and worse overall survival [23••, 26••, 28] . Although the initial therapy for AML has been standardized and forms the backbone of clinical trials, some patients do not receive conventional therapy at diagnosis due to existing or potential comorbidities which may also impact prognosis and health outcomes [8] .
Diabetes is a common comorbidity that occurs with aging [29] . Older patients with comorbid diabetes and cancer have been found to have poorer health outcomes than cancer patients without diabetes [30, 31, 32•] . In older patients with AML, diabetes was found to be adversely associated with 30-day survival rates [28] . Hyperglycemia, defined as a blood glucose ≥ 140 mg/dL [33] , has been noted to occur in up to 38% of hospitalized patients including those with a diagnosis of diabetes and those without diabetes [34] . The onset of hyperglycemia can occur in those with and without a diagnosis of diabetes, a recent review noted 11% of inpatients with no prior history of diabetes experienced hyperglycemia [35••] . Diabetes and/or hyperglycemia are often exacerbated by the administration of glucocorticosteroids as part of the chemotherapy treatment regimen [36] . Standard screening of patients with AML prior to the onset of treatment could be beneficial in predicting and managing those patients who may be at higher risk for exacerbation of their diabetes and/or the development of hyperglycemia. Independent of a diagnosis of diabetes, hyperglycemia has been shown to impact the health outcomes of patients with cancer [37••, 38•] . For example, patients with AML who experienced hyperglycemia were found to have a greater risk for infection, [19••, 39] , sepsis, [40] , longer hospital length of stay [18••], and mortality. However, inconsistencies in definitions and measurement practices between studies make it difficult to interpret the full impact of hyperglycemia on health outcomes [41] .
Comorbidity Measures in AML
There are risk assessments that help to measure the potential impact of comorbidities on health outcomes related to survival and mortality rates. The Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) are frequently used to measure comorbidities [42] . The CCI assigns point values for certain comorbidities, some of which are stratified for severity [42] . The original CCI has been revised slightly for use in older adults with AML [42] . A single-center retrospective study showed that patients with a CCI score > 1 had a significantly lower chance of attaining a complete remission compared to those with a score of 0 or 1 (35 versus 63%, respectively) [42] . The group with higher CCI scores also showed a trend toward higher 8-week mortality and lower 2-year survival [42] . The HCT-CI was developed to improve the sensitivity of the CCI in the stem cell transplant setting, but has been evaluated as a tool to predict outcomes with intensive induction chemotherapy for AML as well [42] . Overall, the importance of comorbidities has not been well established in older patients with AML. However, it has been shown that AML cancer survivors who have comorbid disease(s) experience lower levels of QOL [43] , have poorer physical function, and less able to self-manage their disease [44] . The assessment of comorbidities prior to treatment is critically important to better facilitate choice of treatment options. More research is necessary to determine which comorbid risk assessment tool best identifies the comorbidity or cluster of comorbid conditions that exert the most influence on the health outcomes of older patients with AML. The impact of comorbidities on the severity of symptoms experienced by older patients with AML is unknown. Future research should examine the interaction between a diagnosis of AML, comorbidities, and normal aging health-related issues on symptom severity.
Symptom and Physical Function Changes for Older Adults with AML
Fatigue has been found to be the most common, distressing symptom that has been reported by more than 90% of adults with AML during treatment [45, 46] . Fatigue significantly impacts QOL, leading to restrictions in activities of daily living (ADLs), and is particularly severe during chemotherapy [46, 47] . Hospitalization can be detrimental to adults with AML as it can reduce functional abilities, endurance, and overall health [48, 49] . Functional decline is a major concern for older adults with AML. Irrespective of previous physical ability or frailty, older adults who are hospitalized are at an increased risk for disability [50] . Furthermore, hospital length of stays can be up to 35% longer for those who require assistance from basic activities, such as dressing and bathing, to more complex activities like pain management [51] . A central focus of cancer rehabilitation is improvement of body function, fatigue, and overall QOL [52] [53] [54] . Therefore, exercise has been introduced to various cancer populations during and post-treatment due to its positive impact on physical health, fatigue, symptoms, and functioning.
The American College of Sports Medicine published exercise guidelines for cancer survivors which recommend that survivors of cancer achieve 150 min of moderate to vigorous intensity aerobic activity weekly [55] . There are several physical (symptom reduction) and psychological benefits (decreased anxiety and depressive symptoms) associated with exercise for survivors [55] [56] [57] . Before a patient starts to exercise, a functional assessment is recommended to be completed by professionals such as occupational therapists, physical therapists, recreational therapists, exercise physiologists, or a registered nurse. Common functional measures used in practice and research are Eastern Cooperative Oncology Group (ECOG) and clinician-or patient-rated Karnofsky Performance Scale (KPS) that quantify and capture how well an individual is able to engage in daily activities while having AML and determine how well the individual will be able to tolerate. The geriatric assessment is a more comprehensive approach to assess function as ECOG and KPS are crude assessments of function (Table 1) .
Five exercise studies conducted in patients with AML have shown beneficial effects on cardiorespiratory fitness, muscle strength, and functional mobility [45, [58] [59] [60] [61] . These benefits are critical in ensuring that the patient remains active and functional during their hospitalization and after hospital discharge. Most of these studies involved small sample sizes Table 2) .
Quality of Life in AML
Recognized as one of the most important patient-reported outcomes, QOL includes physical, psychological, emotional, spiritual, and sexual function domains [7, 49, 62 ]. An AML diagnosis may significantly impact QOL of affected individuals, which is underscored by the fact that 97% of patients older than 60 years with AML report that QOL is more important than length of life [62] . Given the short life expectancy of many older patients with AML and the low likelihood of cure, patients may wish to consider the impact of cancer therapy on their QOL [63] . Therefore, maximizing QOL should be an important goal when treating this population and eliciting patient preferences and goals of treatment are necessary to formulate a personalized treatment plan. The optimal target should be to cure the disease without compromising on patient's QOL, as well as maintaining general functioning and cognition in the long term
The psychosocial burden of disease as a psychosocial construct in terms of older patients with AML is huge for the patient, especially during active treatment [1••]. In the context of this paper, the psychological burden of disease refers to the emotional stress of living with a diagnosis of cancer and its treatment, fear of recurrence, and the distress imposed by living with the day-to-day physical problems that can create new or worsen preexisting psychological distress for people living with cancer, their families, and other informal caregivers [64] .
Cancer is a stressful time for both patients and family members who are often expected to deal with cancer-related symptoms [65] . Spirituality, a fundamental element of human experience that encompasses the individual's search for meaning and purpose in life, could be an important factor that helps a person in coping with the disease process [66] . Quality of life may be influenced by an individual's previous health status prior to the cancer diagnosis. Evidence suggests that for "fit" patients, older age is associated with QOL and physical function similar to those of younger patients during and after intensive chemotherapy [20] . Furthermore, coping strategies are an integral role in survivorship, and interventions to enhance effective coping are instrumental to improve adaptation and leukemia survivors' QOL [67] .
Since intensive chemotherapy is known to be rarely beneficial for frail older adults or those with poor-risk disease, AML may be better-managed using palliative care approaches that focus on QOL and symptom management [15, 42] . Despite the poor prognosis associated with AML, palliative care and hospice services are rarely used [63] . This population could benefit from early referral to palliative care concurrently while pursuing induction chemotherapy [63] . For example, patients, who are deemed too frail for myelosuppressive therapy because of multiple comorbidities, may benefit from lowintensity therapies (such as low-dose cytarabine) in conjunction with palliative care [68, 69] . Early integration of palliative care improves QOL and symptom burden and decreases health service utilization in patients with solid malignancies. Employing a similar strategy in older adults with AML may prove valuable in improving QOL and health care delivery [66] .. However, the absence of a clear transition between the curative and palliative phases of disease for older patients with AML may hamper the receipt of hospice services [63] . Research comparing health care utilization and end-of-life care in older patients with AML found that only a minority of patients dying of AML utilized hospice services. The frequent need for blood product support, which many hospice organizations do not permit because of financial constraints, likely contribute to lower rates of hospice referrals [63] . More research is needed to assess the availability and impact of palliative care and hospice services on QOL in this population.
Older adults with AML are commonly underrepresented in clinical trials, often due to poor performance status, abnormal organ function, or active infection [70, 71] . Poor representation in clinical trials leads to inadequate evidence and knowledge about responses of older patients to medications [2, 72] . Major medical breakthroughs in cancer could not happen without the generosity of clinical trial participants young and old; therefore, it is important for research to include participants of different age, sex, race, and ethnicity [72] . The lack of recruitment and participation of older adults in clinical trials results in medical decisions for older adults being routinely based on data derived from studies of younger adults [73] . Older adults represent the fastest-growing population nationwide. Therefore, the evaluation of new treatment therapies in the older adult population is becoming a major issue.
The National Comprehensive Cancer Network, an alliance of leading cancer centers, explicitly state clinical trials as the preferred option in patients with untreated AML who are aged 60 years and older [70] . With longer life expectancy, there is an anticipation that treatments will cure and improve QOL [72] . Hence, there is a clear need for evidence-based interventions for older adults. Evidence-based data ensures that therapies are prescribed to the older patient when they may offer a meaningful gain in survival, QOL, or both, and avoided in situations in which they may not be beneficial [74] .
Conclusions
Caring for the patient holistically is the goal of patient centered care-better management of comorbidities and symptoms can lead to improved physical function, ultimately enhancing QOL. Currently, AML remains a high mortality disease for adults. Additionally, only a few drug studies have incorporated patient-reported outcomes (PROs) and even less have tracked how these change over time. More clinical trial studies that incorporate PROs from older adults with AML are needed to increase our knowledge about ways to improve physical function and maximize QOL because maintaining or improving function during treatment is critical. Inclusion of patients in clinical trials who are frail, unfit, or who have high-risk disease should be strongly encouraged by providers. We encourage oncology providers to incorporate more comprehensive patient assessments tailored to older adults to assess fitness and develop personalized strategies with the interdisciplinary team to improve the care of older adults with AML.
Future Directions
As the population grows older, the number of estimated cases for AML will also rise. Integration of electronic symptoms into routine electronic records and care remains a high priority. Future large scale, multi-centered longitudinal randomized trials are warranted to measure the effects of comorbidities on physical and psychological variables of interest, in addition to QOL. Studies that test self-management interventions such as exercise are also needed to assess its impact on the management of comorbidities, and subsequent improvement of symptoms and physical function, thereby improving QOL for older patients with AML.
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